Galectin-9-Mediated Protection from Allo-Specific T Cells as a Mechanism of Immune Privilege of Corneal Allografts
Graft Rejection
Male
Anterior Chamber
Lymphoid Tissue
Science
Galectins
CD8-Positive T-Lymphocytes
Corneal Transplantation
Mice
03 medical and health sciences
0302 clinical medicine
Animals
Transplantation, Homologous
Hepatitis A Virus Cellular Receptor 2
Cell Death
Q
Endothelium, Corneal
Graft Survival
R
Immunity
Endothelial Cells
3. Good health
Cytoprotection
Medicine
Receptors, Virus
Research Article
DOI:
10.1371/journal.pone.0063620
Publication Date:
2013-05-08T00:54:34Z
AUTHORS (6)
ABSTRACT
The eye is an immune-privileged organ, and corneal transplantation is therefore one of the most successful organ transplantation. The immunosuppressive intraocular microenvironment is known as one of the mechanisms underlying immune privilege in the eye. T-cell immunoglobulin and mucin domain (Tim)-3 is a regulatory molecule for T-cell function, and galectin (Gal)-9 is a Tim-3 ligand. We investigated the role of this pathway in establishing the immune-privileged status of corneal allografts in mice. Gal-9 is constitutively expressed on the corneal epithelium, endothelium and iris-ciliary body in normal mouse eyes and eyes bearing surviving allografts, and Tim-3 was expressed on CD8 T cells infiltrating the allografts. Allograft survival in recipients treated with anti-Tim-3 monoclonal antibody (mAb) or anti-Gal-9 mAb was significantly shorter than that in control recipients. In vitro, destruction of corneal endothelial cells by allo-reactive T cells was enhanced when the cornea was pretreated with anti-Gal-9 mAb. Blockade of Tim-3 or Gal-9 did not abolish anterior chamber-associated immune deviation. We propose that constitutive expression of Gal-9 plays an immunosuppressive role in corneal allografts. Gal-9 expressed on corneal endothelial cells protects them from destruction by allo-reactive T cells within the cornea.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (34)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....